Physician Hesitation to Prescribe Biogen/Eisai's Aduhelm in Alzheimer's Disease Grows Amid Controversies, According to Spherix Global Insights
/PRNewswire/ -- For those of us following the evolution of neurology pharmaceutical markets, 2021 will be remembered by many for the tumultuous roll out of...
Source: prnewswire.com